Drugmakers say they're adjusting their 'thinking on price' of first postpartum depression pill approved in the US | HealthWatch

(CNN) — Drugmakers Sage Therapeutics and Biogen are still ironing out how much their newly approved postpartum depression medication, zuranolone, will cost once it’s made commercially available in the United

Related Keywords

United States ,Barry Greene ,Stacie Dusetzina ,Christophera Viehbacher ,Matt Henson ,Chris Benecchi ,Salim Syed ,Vanderbilt University Medical Center ,Drug Administration ,Cnn ,Us Drug Enforcement Administration ,National Institute Of Mental Health ,Drugmakers Sage Therapeutics ,Sage Therapeutics ,Enforcement Administration ,Wall Street ,Vanderbilt University Medical ,National Institute ,Mental Health ,Healthwatch ,News ,